This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Novartis Ag. Active years: 2024.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2024
Title: Michael Wald - Innovator in Dry Eye Disease Treatment
Introduction
Michael Wald is a notable inventor based in Acton, MA (US). He has made significant contributions to the field of ophthalmology, particularly in the treatment of dry eye disease (DED). His innovative approach focuses on personalized therapies that enhance patient outcomes.
Latest Patents
Wald holds a patent for "Methods of treating dry eye disease using TNF alpha antagonists." This patent outlines novel predictive methods and personalized therapies for treating DED. Specifically, it relates to administering a TNFα antagonist, such as LME636, to patients who are genetically predisposed to respond favorably to this treatment. The patent also includes diagnostic methods and kits that help predict the likelihood of a patient's response to TNFα antagonists.
Career Highlights
Michael Wald is associated with Novartis AG, a leading global healthcare company. His work at Novartis has allowed him to collaborate with other experts in the field, enhancing the development of innovative treatments for eye diseases.
Collaborations
Wald has worked alongside notable colleagues, including Yunsheng He and Christian Leisner. Their combined expertise contributes to advancing research and development in the treatment of dry eye disease.
Conclusion
Michael Wald's contributions to the treatment of dry eye disease through innovative methods and personalized therapies highlight his role as a key inventor in the field. His work continues to pave the way for improved patient care and outcomes.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile